LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

21.03 1.2

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

20.65

Massimo

21.32

Metriche Chiave
By Trading Economics
Entrata	-29M -11M
Vendite	-24M 105M
EPS	-0.09
Margine di Profitto	-10.717
Dipendenti	354
EBITDA	-31M -8.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+66.01% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-433M 2.5B
Apertura precedente	19.83
Chiusura precedente	21.03

Notizie sul Sentiment di mercato

By Acuity

46%

54%

142 / 345 Classifica in Healthcare

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mag 2026, 08:24 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mag 2026, 21:22 UTC

Utili

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mag 2026, 20:50 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:01 UTC

Discorsi di Mercato

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mag 2026, 14:43 UTC

Discorsi di Mercato

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mag 2026, 14:15 UTC

Discorsi di Mercato

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mag 2026, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

25 mag 2026, 12:58 UTC

Discorsi di Mercato

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mag 2026, 12:56 UTC

Discorsi di Mercato

Utili

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mag 2026, 12:34 UTC

Discorsi di Mercato

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mag 2026, 12:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 mag 2026, 11:00 UTC

Discorsi di Mercato

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mag 2026, 10:19 UTC

Discorsi di Mercato

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mag 2026, 10:05 UTC

Utili

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mag 2026, 10:04 UTC

Utili

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mag 2026, 10:03 UTC

Utili

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mag 2026, 10:02 UTC

Utili

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mag 2026, 10:01 UTC

Utili

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mag 2026, 10:00 UTC

Utili

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q EPS MYR0.1883

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Rev MYR17.1B

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Net MYR1.1B

25 mag 2026, 09:38 UTC

Discorsi di Mercato

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mag 2026, 08:55 UTC

Discorsi di Mercato

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

66.01% in crescita

Previsioni per 12 mesi

Media 34.63 USD 66.01%

Alto 36 USD

Basso 33 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

142 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.